DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7a1b9f/idiopathic_pulmona) has announced the addition of GlobalData's new report "Idiopathic Pulmonary Fibrosis (IPF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Idiopathic Pulmonary Fibrosis Therapeutics market. The report identifies the key trends shaping and driving the global Idiopathic Pulmonary Fibrosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Idiopathic Pulmonary Fibrosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Idiopathic Pulmonary Fibrosis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Idiopathic Pulmonary Fibrosis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Idiopathic Pulmonary Fibrosis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Idiopathic Pulmonary Fibrosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Idiopathic Pulmonary Fibrosis Therapeutics market
Companies Mentioned:
- Actelion Ltd.
- Boehringer Ingelheim GmbH
- Celgene Corporation
- Fibrogen, Inc.
- InterMune, Inc.
For more information visit http://www.researchandmarkets.com/research/7a1b9f/idiopathic_pulmona